44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Nanoscience and Nanomedicine

Sign up for email alert when new content gets added: Sign up

Targeted liposomal nanodelivery of E-cadherin as potential therapy for acute myeloid leukaemia

Author(s): Esraa Ibrahim A. Shaaban and Sameh A. Mohammed*

Advanced drug delivery system has opened novel approaches to develop the therapeutic effects of potentially-efficient molecules. Specifically, Lipid Nanoparticles (LNs) have recruited as promising Nano carriers in cancer therapy. LNs exhibit remarkable advantages such as reduced toxicity, high bioavailability of drugs, incorporation versatility of lipophilic and hydrophilic drugs, and large-scale production feasibility. Furthermore, LNs overcome numerous physiological barriers that prohibit drug delivery to tumor location and are also able to curb mechanisms of multidrug resistance, unique characteristics of cancer cells. E-cadherin (CDH1) is an epithelial cadherin, belongs to the calcium-dependent adhesion molecule superfamily, and is implicated in the interactions of hematopoietic progenitors and bone marrow stromal cells. Adhesion capacity to bone marrow stroma was impaired for leukemia cells, suggesting that a breakdown of adhesive mechanisms governed by an adhesion molecule may exist in the leukemic microenvironment. Our Nano formulation mainly consists of liposomal nanoparticles to deliver CDH1 for targeting leukemic cells. LNs can deliver CDH1 by different mechanisms, such as passive mechanisms that take advantage of the tumor microenvironment. After the restoration of E-cadherin in leukemia cells, E-cadherin-specific adhesion was enhanced.

Full-Text | PDF
Google Scholar citation report
Citations : 51

Journal of Nanoscience and Nanomedicine received 51 citations as per Google Scholar report